| 書目名稱 | Farnesyltransferase Inhibitors in Cancer Therapy | | 編輯 | Sa?d M. Sebti,Andrew D. Hamilton | | 視頻video | http://file.papertrans.cn/342/341197/341197.mp4 | | 概述 | Includes supplementary material: | | 叢書名稱 | Cancer Drug Discovery and Development | | 圖書封面 |  | | 描述 | With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints..Illuminating and richly detailed, Farnesyltransferase I | | 出版日期 | Book 2001 | | 關(guān)鍵詞 | biochemistry; cancer; cancer therapy; cardiovascular disease; cell; chemistry; development; drugs; medicinal | | 版次 | 1 | | doi | https://doi.org/10.1007/978-1-59259-013-1 | | isbn_softcover | 978-1-4684-9606-2 | | isbn_ebook | 978-1-59259-013-1Series ISSN 2196-9906 Series E-ISSN 2196-9914 | | issn_series | 2196-9906 | | copyright | Springer Science+Business Media New York 2001 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-13 07:35
發(fā)表于 2025-3-21 19:00:43
